Jefferies raises Globus Medical stock price target on strong quarter

Jefferies raised its price target on Globus Medical Inc. (NYSE:GMED) shares to $120 from $115 while maintaining a Buy rating on the stock on February 25, 2026, citing the company's strong fourth-quarter 2025 performance where sales reached $826.4 million, a 25% increase excluding foreign exchange fluctuations that exceeded analyst expectations. Core revenues reached $727 million, up 9.4%, with the company reporting what it called its best quarterly performance ever in core and enabling technologies. The stock has surged nearly 50% over the past six months, currently trading at $91.88 with a market cap of $12.3 billion. The positive outlook from Jefferies reflects growing confidence in Globus Medical's operational strength, as the integration of NVRO progresses with sales remaining stable despite aggressive cost reductions. The company maintained its fiscal year 2026 sales guidance largely unchanged from January projections while raising its earnings per share guidance by $0.10. According to InvestingPro, the stock appears undervalued at current levels, with 7 analysts recently revising their earnings estimates upward. Jefferies specifically noted that hiring, product momentum, and disrupted competitors are expected to support future performance. Other financial institutions have also expressed optimism following Globus Medical's preliminary fourth-quarter 2025 revenue report of approximately $823.2 million, marking a 25.2% year-over-year growth. Canaccord Genuity raised its price target to $112, maintaining a Buy rating, while Needham upgraded the stock to Buy, highlighting the company's EBITDA margin reaching an estimated 20% and projecting continued margin expansion. Truist Securities increased its price target to $115, citing synergy gains, and TD Cowen initiated coverage with a Buy rating and a price target of $110. Citizens was the outlier, reiterating a Market Perform rating after Globus Medical's preannouncement of its fourth-quarter revenue and initial 2026 guidance, suggesting mixed but generally positive analyst sentiment surrounding the medical device company's prospects.